148 related articles for article (PubMed ID: 29479934)
1. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the management of rh-negative pregnant women.
Duplantie J; Gonzales OM; Bois A; Nshimyumukiza L; Gekas J; Bujold E; Morin V; Vallée M; Giguère Y; Gagné C; Rousseau F; Reinharz D
J Obstet Gynaecol Can; 2013 Aug; 35(8):730-740. PubMed ID: 24007709
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
[TBL] [Abstract][Full Text] [Related]
4. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
6. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
Hawk AF; Chang EY; Shields SM; Simpson KN
Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
[TBL] [Abstract][Full Text] [Related]
7. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
[TBL] [Abstract][Full Text] [Related]
9. [Economic analysis of the prevention of anti-D immunization].
Ravinet J; Carbonne B
J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S104-1S111. PubMed ID: 16495835
[TBL] [Abstract][Full Text] [Related]
10. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
Szczepura A; Osipenko L; Freeman K
BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop.
Clausen FB; Barrett AN;
Vox Sang; 2019 May; 114(4):386-393. PubMed ID: 30834546
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Higgins C; Shehata N; Okun N; de Vrijer B; Pechlivanoglou P; Ng V; Sikich N
J Obstet Gynaecol Can; 2021 Dec; 43(12):1416-1425.e5. PubMed ID: 34390866
[TBL] [Abstract][Full Text] [Related]
14. Economics of antenatal prophylaxis.
Cairns JA
Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():19-22. PubMed ID: 9863974
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of antenatal anti-D prophylaxis.
Vick S; Cairns J; Urbaniak S; Whitfield C; Raafat A
Health Econ; 1996; 5(4):319-28. PubMed ID: 8880168
[TBL] [Abstract][Full Text] [Related]
16. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
[TBL] [Abstract][Full Text] [Related]
17. Cost-benefit analysis of indirect antiglobulin screening in Rh(D)-negative women at 28 weeks of gestation.
Abbey R; Dunsmoor-Su R
Obstet Gynecol; 2014 May; 123(5):938-945. PubMed ID: 24785843
[TBL] [Abstract][Full Text] [Related]
18. The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action.
Visser GHA; Di Renzo GC; Spitalnik SL;
Am J Obstet Gynecol; 2019 Sep; 221(3):227.e1-227.e4. PubMed ID: 31121145
[TBL] [Abstract][Full Text] [Related]
19. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
Pilgrim H; Lloyd-Jones M; Rees A
Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
[TBL] [Abstract][Full Text] [Related]
20. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
